MA27106A1 - Composition pharmaceutique de chlorhydrate de diltiazem stable pour application cutanee et son procede de preparation - Google Patents
Composition pharmaceutique de chlorhydrate de diltiazem stable pour application cutanee et son procede de preparationInfo
- Publication number
- MA27106A1 MA27106A1 MA27807A MA27807A MA27106A1 MA 27106 A1 MA27106 A1 MA 27106A1 MA 27807 A MA27807 A MA 27807A MA 27807 A MA27807 A MA 27807A MA 27106 A1 MA27106 A1 MA 27106A1
- Authority
- MA
- Morocco
- Prior art keywords
- stable
- pharmaceutical composition
- preparing
- same
- diltiazem hydrochloride
- Prior art date
Links
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005316 diltiazem hydrochloride Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 239000012467 final product Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03398006A EP1516622B1 (fr) | 2003-09-18 | 2003-09-18 | Composition pharmaceutique stable de chlorhydrate de diltiazem pour application cutanée et procédé pour sa préparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27106A1 true MA27106A1 (fr) | 2004-12-20 |
Family
ID=34178675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27807A MA27106A1 (fr) | 2003-09-18 | 2004-07-29 | Composition pharmaceutique de chlorhydrate de diltiazem stable pour application cutanee et son procede de preparation |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1516622B1 (fr) |
| AT (1) | ATE376424T1 (fr) |
| BR (1) | BRPI0402223B8 (fr) |
| DE (1) | DE60317063T2 (fr) |
| ES (1) | ES2297111T3 (fr) |
| MA (1) | MA27106A1 (fr) |
| PT (1) | PT1516622E (fr) |
| TN (1) | TNSN04150A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008022032A2 (fr) * | 2006-08-11 | 2008-02-21 | Solvay Pharmaceuticals, Inc. | Compositions pharmaceutiques topiques contenant un bloqueur des canaux calciques et procédé d'utilisation |
| US10960011B2 (en) | 2016-06-23 | 2021-03-30 | Servicio Andaluz De Salud | Compositions for the treatment of ischemic ulcers and stretch marks |
| CN115337258B (zh) * | 2022-07-22 | 2024-10-15 | 上海奥全生物医药科技有限公司 | 一种盐酸地尔硫卓的药物组合物、制备方法及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
| CA2089003C (fr) * | 1990-08-13 | 2001-03-20 | David W. Yesair | Particules colloidales a base de lipidiques mixtes et de bicarbonate pour l'administration de medicaments ou de calories |
| KR20020050135A (ko) * | 2000-12-20 | 2002-06-26 | 조명재 | 피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물 |
-
2003
- 2003-09-18 DE DE60317063T patent/DE60317063T2/de not_active Expired - Lifetime
- 2003-09-18 AT AT03398006T patent/ATE376424T1/de not_active IP Right Cessation
- 2003-09-18 ES ES03398006T patent/ES2297111T3/es not_active Expired - Lifetime
- 2003-09-18 EP EP03398006A patent/EP1516622B1/fr not_active Expired - Lifetime
- 2003-09-18 PT PT03398006T patent/PT1516622E/pt unknown
-
2004
- 2004-06-15 BR BRPI0402223A patent/BRPI0402223B8/pt not_active IP Right Cessation
- 2004-07-29 MA MA27807A patent/MA27106A1/fr unknown
- 2004-08-06 TN TNP2004000150A patent/TNSN04150A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2297111T3 (es) | 2008-05-01 |
| TNSN04150A1 (fr) | 2007-03-12 |
| BRPI0402223B1 (pt) | 2016-10-25 |
| BRPI0402223A (pt) | 2005-06-07 |
| BRPI0402223B8 (pt) | 2021-05-25 |
| EP1516622A1 (fr) | 2005-03-23 |
| EP1516622B1 (fr) | 2007-10-24 |
| ATE376424T1 (de) | 2007-11-15 |
| DE60317063T2 (de) | 2008-08-07 |
| PT1516622E (pt) | 2008-02-04 |
| DE60317063D1 (de) | 2007-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1311285E (pt) | Composicao farmaceutica liquida contendo um derivado de eritropoietina | |
| IL188506A0 (en) | Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease | |
| YU69603A (sh) | Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum | |
| HU0303037D0 (en) | Compounds to treat alzheimer's disease and pharmaceutical compositions containing them | |
| GB0100758D0 (en) | Immunogenic complex method of preparation thereof and pharmaceutical compositions containing the same, useful for disease control | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
| BRPI0407181A (pt) | Formulação farmacêutica | |
| UY27548A1 (es) | Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas | |
| BR9909958A (pt) | Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| HUP0100024A3 (en) | Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient | |
| EP1539718A4 (fr) | Derive de 1,2,4-triazole, son procede de preparation et composition pharmaceutique le contenant | |
| MXPA04005552A (es) | Analogos de vitamina d. | |
| MA27106A1 (fr) | Composition pharmaceutique de chlorhydrate de diltiazem stable pour application cutanee et son procede de preparation | |
| AU2003273310A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease | |
| SE0202692D0 (sv) | Compounds | |
| PT1406859E (pt) | Derivados substituídos de 4-aminociclo-hexanol | |
| FR2851734B1 (fr) | Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede | |
| AU2002223170A1 (en) | Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions | |
| HUP0103149A3 (en) | Pharmaceutical composition for treatment of alzheimer's disease | |
| HUP0402417A3 (en) | N,n'-disubstituted piperazine compounds process for producing them, pharmaceutical compositions containing them and use thereof | |
| DE50212538D1 (de) | Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten | |
| AU2001255234A1 (en) | Cellular calcium responce for diagnosis of alzheimer's disease | |
| HUP0402418A3 (en) | Substituted 1,5-diaminopentan-3-ol compounds, process for producing them, pharmaceutical compositions containing them and use thereof |